Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase

Approximately one-quarter of people over the age of 65 are estimated to suffer some form of cognitive impairment, underscoring the need for effective cognitive-enhancing agents. Insulin-regulated aminopeptidase (IRAP) is potentially an innovative target for the development of cognitive enhancers, as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The FASEB journal Jg. 22; H. 12; S. 4209
Hauptverfasser: Albiston, Anthony L, Morton, Craig J, Ng, Hooi Ling, Pham, Vi, Yeatman, Holly R, Ye, Siying, Fernando, Ruani N, De Bundel, Dimitri, Ascher, David B, Mendelsohn, Frederick A O, Parker, Michael W, Chai, Siew Yeen
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.12.2008
Schlagworte:
ISSN:1530-6860, 1530-6860
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Approximately one-quarter of people over the age of 65 are estimated to suffer some form of cognitive impairment, underscoring the need for effective cognitive-enhancing agents. Insulin-regulated aminopeptidase (IRAP) is potentially an innovative target for the development of cognitive enhancers, as its peptide inhibitors exhibit memory-enhancing effects in both normal and memory-impaired rodents. Using a homology model of the catalytic domain of IRAP and virtual screening, we have identified a class of nonpeptide, small-molecule inhibitors of IRAP. Structure-based computational development of an initial "hit" resulted in the identification of two divergent families of compounds. Subsequent medicinal chemistry performed on the highest affinity compound produced inhibitors with nanomolar affinities (K(i) 20-700 nM) for IRAP. In vivo efficacy of one of these inhibitors was demonstrated in rats with an acute dose (1 nmol in 1 microl) administered into the lateral ventricles, improving performance in both spatial working and recognition memory paradigms. We have identified a family of specific IRAP inhibitors that is biologically active which will be useful both in understanding the physiological role of IRAP and potentially in the development of clinically useful cognitive enhancers. Notably, this study also provides unequivocal proof of principal that inhibition of IRAP results in memory enhancement.
AbstractList Approximately one-quarter of people over the age of 65 are estimated to suffer some form of cognitive impairment, underscoring the need for effective cognitive-enhancing agents. Insulin-regulated aminopeptidase (IRAP) is potentially an innovative target for the development of cognitive enhancers, as its peptide inhibitors exhibit memory-enhancing effects in both normal and memory-impaired rodents. Using a homology model of the catalytic domain of IRAP and virtual screening, we have identified a class of nonpeptide, small-molecule inhibitors of IRAP. Structure-based computational development of an initial "hit" resulted in the identification of two divergent families of compounds. Subsequent medicinal chemistry performed on the highest affinity compound produced inhibitors with nanomolar affinities (K(i) 20-700 nM) for IRAP. In vivo efficacy of one of these inhibitors was demonstrated in rats with an acute dose (1 nmol in 1 microl) administered into the lateral ventricles, improving performance in both spatial working and recognition memory paradigms. We have identified a family of specific IRAP inhibitors that is biologically active which will be useful both in understanding the physiological role of IRAP and potentially in the development of clinically useful cognitive enhancers. Notably, this study also provides unequivocal proof of principal that inhibition of IRAP results in memory enhancement.
Approximately one-quarter of people over the age of 65 are estimated to suffer some form of cognitive impairment, underscoring the need for effective cognitive-enhancing agents. Insulin-regulated aminopeptidase (IRAP) is potentially an innovative target for the development of cognitive enhancers, as its peptide inhibitors exhibit memory-enhancing effects in both normal and memory-impaired rodents. Using a homology model of the catalytic domain of IRAP and virtual screening, we have identified a class of nonpeptide, small-molecule inhibitors of IRAP. Structure-based computational development of an initial "hit" resulted in the identification of two divergent families of compounds. Subsequent medicinal chemistry performed on the highest affinity compound produced inhibitors with nanomolar affinities (K(i) 20-700 nM) for IRAP. In vivo efficacy of one of these inhibitors was demonstrated in rats with an acute dose (1 nmol in 1 microl) administered into the lateral ventricles, improving performance in both spatial working and recognition memory paradigms. We have identified a family of specific IRAP inhibitors that is biologically active which will be useful both in understanding the physiological role of IRAP and potentially in the development of clinically useful cognitive enhancers. Notably, this study also provides unequivocal proof of principal that inhibition of IRAP results in memory enhancement.Approximately one-quarter of people over the age of 65 are estimated to suffer some form of cognitive impairment, underscoring the need for effective cognitive-enhancing agents. Insulin-regulated aminopeptidase (IRAP) is potentially an innovative target for the development of cognitive enhancers, as its peptide inhibitors exhibit memory-enhancing effects in both normal and memory-impaired rodents. Using a homology model of the catalytic domain of IRAP and virtual screening, we have identified a class of nonpeptide, small-molecule inhibitors of IRAP. Structure-based computational development of an initial "hit" resulted in the identification of two divergent families of compounds. Subsequent medicinal chemistry performed on the highest affinity compound produced inhibitors with nanomolar affinities (K(i) 20-700 nM) for IRAP. In vivo efficacy of one of these inhibitors was demonstrated in rats with an acute dose (1 nmol in 1 microl) administered into the lateral ventricles, improving performance in both spatial working and recognition memory paradigms. We have identified a family of specific IRAP inhibitors that is biologically active which will be useful both in understanding the physiological role of IRAP and potentially in the development of clinically useful cognitive enhancers. Notably, this study also provides unequivocal proof of principal that inhibition of IRAP results in memory enhancement.
Author Fernando, Ruani N
De Bundel, Dimitri
Ng, Hooi Ling
Yeatman, Holly R
Mendelsohn, Frederick A O
Parker, Michael W
Morton, Craig J
Albiston, Anthony L
Chai, Siew Yeen
Ye, Siying
Pham, Vi
Ascher, David B
Author_xml – sequence: 1
  givenname: Anthony L
  surname: Albiston
  fullname: Albiston, Anthony L
  organization: Howard Florey Institute, University of Melbourne, Parkville, VIC 3010, Australia
– sequence: 2
  givenname: Craig J
  surname: Morton
  fullname: Morton, Craig J
– sequence: 3
  givenname: Hooi Ling
  surname: Ng
  fullname: Ng, Hooi Ling
– sequence: 4
  givenname: Vi
  surname: Pham
  fullname: Pham, Vi
– sequence: 5
  givenname: Holly R
  surname: Yeatman
  fullname: Yeatman, Holly R
– sequence: 6
  givenname: Siying
  surname: Ye
  fullname: Ye, Siying
– sequence: 7
  givenname: Ruani N
  surname: Fernando
  fullname: Fernando, Ruani N
– sequence: 8
  givenname: Dimitri
  surname: De Bundel
  fullname: De Bundel, Dimitri
– sequence: 9
  givenname: David B
  surname: Ascher
  fullname: Ascher, David B
– sequence: 10
  givenname: Frederick A O
  surname: Mendelsohn
  fullname: Mendelsohn, Frederick A O
– sequence: 11
  givenname: Michael W
  surname: Parker
  fullname: Parker, Michael W
– sequence: 12
  givenname: Siew Yeen
  surname: Chai
  fullname: Chai, Siew Yeen
BackLink https://www.ncbi.nlm.nih.gov/pubmed/18716029$$D View this record in MEDLINE/PubMed
BookMark eNpN0LtPwzAQBnALFdEHbMzIE1uKncSOPaKKl1SJBebIj0t7VeKUOKGCv55IbSWmO51-3w3fnExCG4CQW86WnGn5UO2WTCWcp2laXJAZFxlLpJJs8m-fknmMO8YYZ1xekSlXBZcs1TNyePMQeqzQmR7bQE3w1G1NZ1wPHf4ej21FDQ1woK7dBOzxGyiErQkOOmpNBE9HhGGLFs8eQxxqDEkHm6E2_UhMg6Hdw75HP0auyWVl6gg3p7kgn89PH6vXZP3-8rZ6XCcu16pIMq9Sb52QLBfCy4xJAUpxLbUspGAu55XXosgzK6wSUmovtM-FyY21wApIF-T--HfftV8DxL5sMDqoaxOgHWIptcrHluQI705wsA34ct9hY7qf8lxV-gcQ223g
CitedBy_id crossref_primary_10_3389_fphar_2020_590855
crossref_primary_10_3390_ijms252212016
crossref_primary_10_1007_s00115_009_2801_6
crossref_primary_10_1021_jm100793t
crossref_primary_10_1111_jnc_14880
crossref_primary_10_1016_j_pneurobio_2011_07_001
crossref_primary_10_1038_srep29575
crossref_primary_10_12688_f1000research_160416_1
crossref_primary_10_12688_f1000research_160416_2
crossref_primary_10_3390_ijms25074084
crossref_primary_10_1007_s00424_012_1102_2
crossref_primary_10_1111_j_1476_5381_2011_01402_x
crossref_primary_10_1002_med_21323
crossref_primary_10_1084_jem_20160534
crossref_primary_10_1124_pr_114_010454
crossref_primary_10_1021_acs_jcim_5b00359
crossref_primary_10_1016_j_neulet_2016_06_034
crossref_primary_10_1515_enr_2016_0025
crossref_primary_10_1016_j_jmb_2024_168449
crossref_primary_10_1021_jm200036n
crossref_primary_10_3233_JAD_171119
crossref_primary_10_1016_j_humimm_2018_11_002
crossref_primary_10_1016_j_cbpa_2014_08_007
crossref_primary_10_1002_open_201402027
crossref_primary_10_3390_ijms23094961
crossref_primary_10_1093_nar_gkw390
crossref_primary_10_3389_fphar_2020_585838
crossref_primary_10_1111_j_1471_4159_2009_06547_x
crossref_primary_10_1016_j_jaci_2023_01_014
crossref_primary_10_1073_pnas_1309781110
crossref_primary_10_1016_j_jinorgbio_2012_02_015
crossref_primary_10_1155_2012_789671
crossref_primary_10_1124_mol_115_102533
crossref_primary_10_1042_BST20160422
crossref_primary_10_1016_j_ejmech_2019_04_027
crossref_primary_10_1016_j_bbagen_2016_09_020
crossref_primary_10_1093_jb_mvab009
crossref_primary_10_1016_j_pneurobio_2014_11_004
crossref_primary_10_1111_j_2042_7158_2010_01247_x
crossref_primary_10_1007_s00706_016_1733_7
crossref_primary_10_1089_adt_2016_708
crossref_primary_10_1002_pro_2604
crossref_primary_10_1016_j_pneurobio_2014_10_001
crossref_primary_10_1002_jcc_21307
crossref_primary_10_1002_med_21449
crossref_primary_10_1016_j_peptides_2009_07_019
crossref_primary_10_1038_gene_2014_46
crossref_primary_10_1089_neu_2011_1824
crossref_primary_10_3390_ph14060584
crossref_primary_10_3389_fimmu_2024_1466692
crossref_primary_10_1002_open_201900344
crossref_primary_10_3389_fmolb_2021_625274
crossref_primary_10_3390_ijms25052516
crossref_primary_10_3389_fcell_2020_585237
crossref_primary_10_1002_pro_5151
crossref_primary_10_1016_j_nlm_2009_07_011
crossref_primary_10_1016_j_yhbeh_2011_12_014
crossref_primary_10_1016_j_expneurol_2019_113076
crossref_primary_10_1038_nrendo_2015_6
crossref_primary_10_1002_ejoc_201402003
crossref_primary_10_1039_D5MD00438A
crossref_primary_10_1055_a_2562_7204
crossref_primary_10_1080_17460441_2017_1322579
crossref_primary_10_1016_j_ejphar_2012_02_048
crossref_primary_10_1016_j_nlm_2016_09_017
crossref_primary_10_1124_pharmrev_120_000281
crossref_primary_10_1038_srep19848
crossref_primary_10_1038_s41598_023_46072_5
crossref_primary_10_1124_mol_110_065458
crossref_primary_10_1111_febs_14009
crossref_primary_10_3233_JAD_161265
crossref_primary_10_1016_j_mce_2008_11_015
crossref_primary_10_1016_j_jocn_2017_08_055
crossref_primary_10_3389_fphar_2020_585930
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1096/fj.08-112227
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Biology
EISSN 1530-6860
ExternalDocumentID 18716029
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-DZ
-~X
.55
0R~
0VX
123
18M
1OB
1OC
29H
2WC
33P
34G
39C
3O-
4.4
53G
5GY
5RE
85S
AAHHS
AAHQN
AAMNL
AANLZ
AAYCA
ABCUV
ABDNZ
ABEFU
ABJNI
ABOCM
ACCFJ
ACCZN
ACGFS
ACIWK
ACNCT
ACPOU
ACPRK
ACXQS
ACYGS
ADKYN
ADZMN
AEEZP
AEIGN
AENEX
AEQDE
AEUYR
AFFNX
AFFPM
AFRAH
AFWVQ
AGCDD
AHBTC
AI.
AITYG
AIURR
AIWBW
AIZAD
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMYDB
BFHJK
BIYOS
C1A
CGR
CS3
CUY
CVF
DCZOG
DU5
D~5
E3Z
EBS
ECM
EIF
EJD
F5P
F9R
FRP
H13
HGLYW
HZ~
H~9
J5H
L7B
LATKE
LEEKS
MEWTI
MVM
NEJ
NPM
O9-
OHT
OVD
Q-A
RHF
RHI
RJQFR
ROL
SAMSI
SJN
SUPJJ
TEORI
TFA
TR2
TWZ
U18
VH1
VXZ
W8F
WH7
WHG
WOQ
WXSBR
X7M
XJT
XOL
XSW
Y6R
YBU
YCJ
YHG
YKV
YNH
YSK
Z0Y
Z5M
ZCA
ZE2
ZGI
ZXP
~KM
7X8
AAMMB
ADXHL
AEFGJ
AEYWJ
AGXDD
AGYGG
AIDQK
AIDYY
ID FETCH-LOGICAL-c4987-3d82dbc560455d63065e88196967650c41fd95743b5b85669d59d45a4abbe07e2
IEDL.DBID 7X8
ISICitedReferencesCount 98
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000261254800020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1530-6860
IngestDate Sun Nov 09 12:38:50 EST 2025
Wed Feb 19 01:52:05 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4987-3d82dbc560455d63065e88196967650c41fd95743b5b85669d59d45a4abbe07e2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 18716029
PQID 69845306
PQPubID 23479
ParticipantIDs proquest_miscellaneous_69845306
pubmed_primary_18716029
PublicationCentury 2000
PublicationDate December 2008
PublicationDateYYYYMMDD 2008-12-01
PublicationDate_xml – month: 12
  year: 2008
  text: December 2008
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The FASEB journal
PublicationTitleAlternate FASEB J
PublicationYear 2008
SSID ssj0001016
Score 2.2803319
Snippet Approximately one-quarter of people over the age of 65 are estimated to suffer some form of cognitive impairment, underscoring the need for effective...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 4209
SubjectTerms Animals
Biological Assay
Catalytic Domain
Cystinyl Aminopeptidase - antagonists & inhibitors
Drug Design
Enzyme Inhibitors - pharmacology
Male
Memory - drug effects
Models, Molecular
Nootropic Agents - pharmacology
Rats
Rats, Sprague-Dawley
Recognition (Psychology) - drug effects
Title Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase
URI https://www.ncbi.nlm.nih.gov/pubmed/18716029
https://www.proquest.com/docview/69845306
Volume 22
WOSCitedRecordID wos000261254800020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwED4VChIL70d5emANJKnT2BISQoiKhaoDSN0qP9Ug4ZSWh_j3nOOkTIiBJdNZspzz-Tv7u_sAzqnArEdxixspjiMqlI6YFf4azmbKxFSkXFRiE_lgwEYjPmzBVVML42mVTUysArUulb8jv-xxRjPEt9fT18hrRvm31VpAYwnaXQ9k0Jvz0U-vcJ-Xhm6pmCCxXlzT3hGzX9rnC9_VNPGFoL9Dy-qI6W_8b3KbsF5DS3ITfGELWsZtw2oQm_zagc9Qk2vrSzoinCZq0a45VGOS0hJBEGmTBa2IGDfxnjEj_sDTBI0KNylk0djXbPZoFlTt0US8FK6cerqMxiG78NS_e7y9j2rZhUhR7kOOZqmWCqEQzTLd89LyhrGqjU6OeE7RxGqeIfKQmWSIBrnOuKaZoEJKE-cm3YNlVzpzAMR0JSaMJpeMJxSHCMR33GDYMInFzJR14KxZzzG6tX-rEM6U7_Nxs6Id2A-_ZDwN3TfGiU_x4pQf_jn2CNYqdkdFPjmGtsUNbU5gRX28FfPZaeUt-B0MH74Bl5jK_A
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+and+characterization+of+a+new+cognitive+enhancer+based+on+inhibition+of+insulin-regulated+aminopeptidase&rft.jtitle=The+FASEB+journal&rft.au=Albiston%2C+Anthony+L&rft.au=Morton%2C+Craig+J&rft.au=Ng%2C+Hooi+Ling&rft.au=Pham%2C+Vi&rft.date=2008-12-01&rft.eissn=1530-6860&rft.volume=22&rft.issue=12&rft.spage=4209&rft_id=info:doi/10.1096%2Ffj.08-112227&rft_id=info%3Apmid%2F18716029&rft_id=info%3Apmid%2F18716029&rft.externalDocID=18716029
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1530-6860&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1530-6860&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1530-6860&client=summon